Drug intelligence / Profile preview

SM06

Development stage: Preclinical
Lead developer: Sinomab Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SM06 is a monoclonal antibody drug candidate developed by Sinomab Bioscience. It targets CD22, acting as a CD22 inhibitor. The primary therapeutic areas under investigation for SM06 are immune system diseases, specifically Sjogren's syndrome and systemic lupus erythematosus. As of the latest available information, SM06 is in preclinical development and has not yet entered clinical trials or received regulatory approval[3].

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on SM06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM06.

Explore the full profile